Home HOME Neoplasma 2020 Neoplasma Vol.67, No.1, p.78–84, 2020

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.1, p.78–84, 2020

Title: High eukaryotic translation elongation factor 1 alpha 1 expression promotes proliferation and predicts poor prognosis in clear cell renal cell carcinoma
Author: Y. Bao, T. L. Zhao, Z. Q. Zhang, X. L. Liang, Z. X. Wang, Y. Xiong, X. Lu, L. H. Wang

Abstract: Accumulating evidence indicates that eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) is involved in cancer, while the clinical significance and the exact role of eEF1A1 in renal cell carcinoma (RCC) remain obscure. The aim of the present study was to evaluate the clinical significance of eEF1A1 in RCC and to investigate its effective mechanisms in order to identify a potential therapeutic target. The expression levels of eEF1A1 in RCC were explored by immunohistochemistry in tissues from 184 patients. eEF1A1 was knocked down, and cell proliferation and apoptosis were then investigated. The MAPK pathway-related proteins were detected by western blot. Our results revealed that eEF1A1 was highly expressed in RCC tissues and associated with poor prognosis. Knockdown of eEF1A1 attenuated proliferation and promoted the apoptosis of RCC cells. Furthermore, eEF1A1 knockdown decreased the phosphorylation level of AKT and ERK. In conclusion, eEF1A1 may serve as a valuable prognostic biomarker and promising therapeutic target of RCC.

Keywords: clear cell renal cell carcinoma, eEF1A1, biomarker, AKT, ERK
Published online: 29-Jan-2020
Year: 2020, Volume: 67, Issue: 1 Page From: 78, Page To: 84

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.